Form 4: RA Capital Increases Stake in Artiva Biotherapeutics

RA Capital Management has reported significant open-market purchases of Artiva Biotherapeutics common stock.

Summary

• RA Capital Management, L.P. acquired a total of 531,326 shares of Artiva Biotherapeutics (ARTV) common stock between June 12, 2026, and June 16, 2026.
• The purchases were executed at weighted average prices ranging from $8.57 to $8.99 per share.
• Following these transactions, the reporting entities beneficially own 16,763,043 shares of common stock held by the Fund, with additional holdings across other managed accounts.
• The reporting group includes RA Capital Healthcare Fund, RA Capital Nexus Fund, RA Capital Nexus III Fund, Peter Kolchinsky, and Rajeev Shah.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive development, as significant open-market buying by a major institutional shareholder typically reflects strong conviction in the company's future prospects.

Positives

• Strong signal of insider and institutional confidence as a major shareholder increases its equity position.
• The acquisition of over 530,000 shares demonstrates long-term commitment to the issuer's growth strategy.

Negatives

• None identified in this filing.

Risks

• Market volatility associated with the biotech sector.
• Concentration of ownership by a single investment firm may influence future corporate governance decisions.

Future Outlook

The filing does not provide forward-looking guidance regarding the company's operations, but the increased stake suggests the reporting person maintains a positive outlook on the issuer's valuation.

Management Comments

• The reporting persons undertake to provide full information regarding the number of shares purchased at each separate price within the reported ranges upon request.

Industry Context

StockSavvy.ai notes that institutional accumulation by specialized healthcare funds like RA Capital is often viewed as a bullish indicator for clinical-stage biotech companies, suggesting confidence in the underlying pipeline or upcoming milestones.

Comparison to Industry Standards

• The behavior aligns with standard institutional investment patterns in the biotech sector where lead investors increase positions to support capital structure or signal confidence ahead of clinical data.
• The purchase prices are consistent with recent market trading ranges for small-cap biotechnology equities.

Related Party Transactions

• Laura Stoppel, a Principal of the Adviser, serves on the Issuer's board of directors.

Stakeholder Impact

• Shareholders may perceive the increased institutional ownership as a stabilizing factor for the stock price.

Next Steps

• Continued monitoring of Form 4 filings for further accumulation or divestment activity by RA Capital.

Key Dates

Recommendation

Institutional accumulation by a sophisticated healthcare investor like RA Capital often precedes positive sentiment shifts, making this a constructive signal for investors.

Keywords

Artiva Biotherapeutics, ARTV, RA Capital Management, Insider Buying, Biotech, SEC Form 4